Cargando…
Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation
Celecoxib (CXB) is a Biopharmaceutical Classification System (BCS) Class II molecule with high permeability that is practically insoluble in water. Because of the poor water solubility, there is a wide range of absorption and limited bioavailability following oral administration. These unfavorable p...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964073/ https://www.ncbi.nlm.nih.gov/pubmed/36839685 http://dx.doi.org/10.3390/pharmaceutics15020363 |
_version_ | 1784896412534702080 |
---|---|
author | Arslan, Aslıhan Yet, Barbaros Nemutlu, Emirhan Akdağ Çaylı, Yağmur Eroğlu, Hakan Öner, Levent |
author_facet | Arslan, Aslıhan Yet, Barbaros Nemutlu, Emirhan Akdağ Çaylı, Yağmur Eroğlu, Hakan Öner, Levent |
author_sort | Arslan, Aslıhan |
collection | PubMed |
description | Celecoxib (CXB) is a Biopharmaceutical Classification System (BCS) Class II molecule with high permeability that is practically insoluble in water. Because of the poor water solubility, there is a wide range of absorption and limited bioavailability following oral administration. These unfavorable properties can be improved using dry co-milling technology, which is an industrial applicable technology. The purpose of this study was to develop and optimize CXB nanoformulations prepared by dry co-milling technology, with a quality by design approach to maintain enhanced solubility, dissolution rate, and oral bioavailability. The resulting co-milled CXB composition using povidone (PVP), mannitol (MAN) and sodium lauryl sulfate (SLS) showed the maximum solubility and dissolution rate in physiologically relevant media. Potential risk factors were determined with an Ishikawa diagram, important risk factors were selected with Plackett-Burman experimental design, and CXB compositions were optimized with Central Composite design (CCD) and Bayesian optimization (BO). Physical characterization, intrinsic dissolution rate, solubility, and stability experiments were used to evaluate the optimized co-milled CXB compositions. Dissolution and permeability studies were carried out for the resulting CXB nanoformulation. Oral pharmacokinetic studies of the CXB nanoformulation and reference product were performed in rats. The results of in vitro and in vivo studies show that the CXB nanoformulations have enhanced solubility (over 4.8-fold (8.6 ± 1.06 µg/mL vs. 1.8 ± 0.33 µg/mL) in water when compared with celecoxib pure powder), and dissolution rate (at least 85% of celecoxib is dissolved in 20 min), and improved oral pharmacokinetic profile (the relative bioavailability was 145.2%, compared to that of Celebrex(®), and faster t(max) 3.80 ± 2.28 h vs. 6.00 ± 3.67 h, indicating a more rapid absorption rate). |
format | Online Article Text |
id | pubmed-9964073 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99640732023-02-26 Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation Arslan, Aslıhan Yet, Barbaros Nemutlu, Emirhan Akdağ Çaylı, Yağmur Eroğlu, Hakan Öner, Levent Pharmaceutics Article Celecoxib (CXB) is a Biopharmaceutical Classification System (BCS) Class II molecule with high permeability that is practically insoluble in water. Because of the poor water solubility, there is a wide range of absorption and limited bioavailability following oral administration. These unfavorable properties can be improved using dry co-milling technology, which is an industrial applicable technology. The purpose of this study was to develop and optimize CXB nanoformulations prepared by dry co-milling technology, with a quality by design approach to maintain enhanced solubility, dissolution rate, and oral bioavailability. The resulting co-milled CXB composition using povidone (PVP), mannitol (MAN) and sodium lauryl sulfate (SLS) showed the maximum solubility and dissolution rate in physiologically relevant media. Potential risk factors were determined with an Ishikawa diagram, important risk factors were selected with Plackett-Burman experimental design, and CXB compositions were optimized with Central Composite design (CCD) and Bayesian optimization (BO). Physical characterization, intrinsic dissolution rate, solubility, and stability experiments were used to evaluate the optimized co-milled CXB compositions. Dissolution and permeability studies were carried out for the resulting CXB nanoformulation. Oral pharmacokinetic studies of the CXB nanoformulation and reference product were performed in rats. The results of in vitro and in vivo studies show that the CXB nanoformulations have enhanced solubility (over 4.8-fold (8.6 ± 1.06 µg/mL vs. 1.8 ± 0.33 µg/mL) in water when compared with celecoxib pure powder), and dissolution rate (at least 85% of celecoxib is dissolved in 20 min), and improved oral pharmacokinetic profile (the relative bioavailability was 145.2%, compared to that of Celebrex(®), and faster t(max) 3.80 ± 2.28 h vs. 6.00 ± 3.67 h, indicating a more rapid absorption rate). MDPI 2023-01-20 /pmc/articles/PMC9964073/ /pubmed/36839685 http://dx.doi.org/10.3390/pharmaceutics15020363 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Arslan, Aslıhan Yet, Barbaros Nemutlu, Emirhan Akdağ Çaylı, Yağmur Eroğlu, Hakan Öner, Levent Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation |
title | Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation |
title_full | Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation |
title_fullStr | Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation |
title_full_unstemmed | Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation |
title_short | Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation |
title_sort | celecoxib nanoformulations with enhanced solubility, dissolution rate, and oral bioavailability: experimental approaches over in vitro/in vivo evaluation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964073/ https://www.ncbi.nlm.nih.gov/pubmed/36839685 http://dx.doi.org/10.3390/pharmaceutics15020363 |
work_keys_str_mv | AT arslanaslıhan celecoxibnanoformulationswithenhancedsolubilitydissolutionrateandoralbioavailabilityexperimentalapproachesoverinvitroinvivoevaluation AT yetbarbaros celecoxibnanoformulationswithenhancedsolubilitydissolutionrateandoralbioavailabilityexperimentalapproachesoverinvitroinvivoevaluation AT nemutluemirhan celecoxibnanoformulationswithenhancedsolubilitydissolutionrateandoralbioavailabilityexperimentalapproachesoverinvitroinvivoevaluation AT akdagcaylıyagmur celecoxibnanoformulationswithenhancedsolubilitydissolutionrateandoralbioavailabilityexperimentalapproachesoverinvitroinvivoevaluation AT erogluhakan celecoxibnanoformulationswithenhancedsolubilitydissolutionrateandoralbioavailabilityexperimentalapproachesoverinvitroinvivoevaluation AT onerlevent celecoxibnanoformulationswithenhancedsolubilitydissolutionrateandoralbioavailabilityexperimentalapproachesoverinvitroinvivoevaluation |